Bispecific Antibodies in Cancer Care: Practical Guidance for the Multidisciplinary Team (Atlanta)

Atlanta, GA US
September 9, 2025

Overview

This interactive, 2-hour CME/CE-certified symposium will equip the multidisciplinary oncology team with practical strategies for integrating bispecific antibodies into the care of patients with cancer. Through expert-led presentations, panel discussions, case examples, and audience engagement, participants will explore:

  • Current and emerging bispecific therapies
  • Strategies for toxicity mitigation and management
  • Transitioning bispecific administration from inpatient to outpatient setting

The program aims to provide actionable insights for both academic and community-based cancer centers to address logistical, resourcing, and patient-care considerations to support the development of an outpatient clinic.

In this how-to session, learners will:

  • Interact with national and local/regional experts in bispecific care
  • Receive tips to streamline and avoid errors in the design of an outpatient bispecific clinic
  • Fine-tune skills in the delivery of outpatient bispecifics
  • Gain insights to expedite reimbursements for outpatient bispecifics

Learning Objectives

  1. Summarize the current clinical applications of bispecific antibodies in the treatment of patients with cancer.
  2. Discuss efficacy and expected outcomes with patients who are considering treatment with a bispecific antibody.
  3. Implement appropriate dosing and administration strategies for patients undergoing treatment with bispecific antibodies in the inpatient and outpatient settings.
  4. Manage treatment-related adverse events associated with bispecific antibody therapy. 

Target Audience

This activity is designed to educate the multidisciplinary team including academic and community hematologists, oncologists, and hem/onc APPs, including nurse practitioners, physician assistants, pharmacists, and nurse specialists.

ATTENTION:  This limited-seating event is open exclusively for clinicians actively practicing in oncology as well as those cancer center employees directly involved in the design and development of outpatient clinics where bispecifics are administered to patients.  No pharmaceutical representatives will be seated for this event and their registrations will be declined.  We thank you for your understanding.

This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. 

Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email, mailing address, and payment information). This information is confidential and will only be used to contact you regarding your registration.

Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 2.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 2.00 credit.
  • 0.75 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.
Course opens: 
07/17/2025
Course expires: 
10/10/2025
Event starts: 
09/09/2025 - 3:30pm PDT
Event ends: 
09/09/2025 - 5:30pm PDT
Cost:
$0.00
Rating: 
0

Commercial support:  This program is supported by independent educational grants from Regeneron Pharmaceuticals, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Please note: times are subject to change. Please check the syllabus for the most current version of the agenda upon arriving at the summit.

All Times Listed are for the Eastern Standard Time Zone

Tuesday, September 9, 2025

6:30pmWelcome & Introductions
6:40pmBispecific Antibodies: Past, Present, and Future
» Sarah Scott, PharmD, BCOP - Clinical Pharmacy Specialist - Emory Winship Cancer Institute
6:55pmMitigation and Management of Bispecific Antibody Toxicities in Myeloma & Lymphoma
» Danielle Roberts, PA-C - Associate Director of Education and Professional Development Emory Healthcare Office of Advanced Practice Providers Malignant Hematology- Winship Cancer Institute Adjunct Faculty and Society Leader for Emory Physician Assistant Program
 7:20pm  Panel Discussion: Anticipating Toxicities with Bispecific Antibody Therapy
  » Sarah Scott, PharmD, BCOP - Clinical Pharmacy Specialist - Emory Winship Cancer Institute
  » Danielle Roberts, PA-C - Associate Director of Education and Professional Development Emory Healthcare Office of Advanced Practice Providers Malignant Hematology- Winship Cancer Institute Adjunct Faculty and Society Leader for Emory Physician Assistant Program
  » Ajay Nooka, MD, MPH, FAC - Associate Professor - Department of Hematology and Medical Oncology - Emory Winship Cancer Institute
  » Sherine Thomas, MD - Georgia Cancer Specialist
7:35pmEffective Implementation of Bispecific Antibodies
» Ajay Nooka, MD, MPH, FAC - Associate Professor - Department of Hematology and Medical Oncology - Emory Winship Cancer Institute
 8:00pm  Panel Discussion: Operationalizing Bispecific Antibody Delivery
  » Sarah Scott, PharmD, BCOP - Clinical Pharmacy Specialist - Emory Winship Cancer Institute
  » Danielle Roberts, PA-C - Associate Director of Education and Professional Development Emory Healthcare Office of Advanced Practice Providers Malignant Hematology- Winship Cancer Institute Adjunct Faculty and Society Leader for Emory Physician Assistant Program
  » Ajay Nooka, MD, MPH, FAC - Associate Professor - Department of Hematology and Medical Oncology - Emory Winship Cancer Institute
  » Sherine Thomas, MD - Georgia Cancer Specialist
8:20pmKey Takeaways and Final Audience Q&A
Maggiano's Little Italy Perimeter
4400 Ashford Dunwoody Rd.
Atlanta, GA 30346
United States

 

 

Faculty Presenters


Sarah Scott, PharmD, BCOP

Clinical Pharmacy Specialist
Emory Winship Cancer Institute
Atlanta, GA

Dr. Sara Scott is a board-certified Clinical Pharmacy Specialist in Multiple Myeloma at Emory Winship Cancer Institute. She received a B.S. in Biomedical Engineering at the University of Utah. She completed her PharmD at The University of North Carolina at Chapel Hill. After school, she completed her PGY1 Pharmacy Residency at Vanderbilt University Medical Center in Nashville, TN and her PGY2 Oncology Pharmacy Residency at The University of Kansas Health System in Kansas City, KS. She is an active member of HOPA and ASTCT. Her professional interests include multiple myeloma, bone marrow transplant, and cellular therapy.


Danielle Roberts, PA-C

Associate Chief of Education for APPs,
Co-Director Hematology/Oncology APP Fellowship
Winship Cancer Institute at Emory University
Atlanta, GA

Danielle Roberts is the Associate Director of Professional Development and Education at Emory Healthcare. She graduated from Emory University’s Physician Assistant Program in 2007 and initially worked in community oncology before joining the Winship Cancer Institute in 2011. Over the years, Danielle has gained experience in a variety of oncologic specialties, including Community Oncology, Survivorship, GVHD, and her current role in Malignant Hematology. In addition to her clinical work, Danielle serves as a Society Leader and adjunct faculty member for the Emory University Physician Assistant Program. She recently completed the 2024 WHEA Teaching Fellowship and was honored as Emory Healthcare’s APP Educator of the Year the same year. Danielle’s passion for education and professional development continues to drive her impact within the healthcare community.


Ajay Nooka, MD, MPH, FACP

Associate Professor 
Department of Hematology and Medical Oncology
Emory Winship Cancer Institute
Atlanta, GA

Ajay Nooka, MD is a Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. He earned his medical degree from Andhra Medical College in India before relocating to the United States. He received a Masters’ in Public Health from the University of Texas School of Public Health in Houston, Texas and then completed his internship and residency at the Northeastern Ohio University College of Medicine, Ohio. He pursued a fellowship in Hematology and Oncology at Emory University School of Medicine in Atlanta, Georgia where he also served as Chief Fellow before he joined faculty. Board certified in Hematology and Medical oncology, Dr. Nooka is the Director of the Myeloma Program at Department of Hematology & Oncology, Emory University and primarily focuses on multiple myeloma treatment and research.

Dr. Nooka is the Associate Director for Clinical Research at Winship Cancer Institute. He is involved in numerous professional organizations, including the International Myeloma Working Group of International Myeloma Society, American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapies. Dr. Nooka’s interests as a clinical investigator focuses on multiple myeloma and bone marrow transplant. His research interests include integrating molecular and clinical data to risk-stratify myeloma; and to evaluate newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients.

In addition to leading several investigator-initiated and industry-sponsored clinical trials, he is a recipient of several awards and grants and has published more than 300 articles and abstracts in high quality peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Blood, Leukemia, Lancet Oncology, Blood Advances, Blood Cancer Journal and Cancer. He serves as a ‘Section Editor’ for the American Cancer Society journal Cancer and associate editor for Clinical Lymphoma, Myeloma and Leukemia, on serves on the editorial board of the American Journal of Clinical Oncology. He is an invited or ad hoc reviewer for several prestigious journals including Journal of Clinical Oncology, Lancet Oncology, Leukemia, Cancer, Blood Advances, Blood Cancer Journal, American Journal of Hematology, British Journal of Hematology, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation.


Sherine Thomas, MD

Georgia Cancer Specialists
Atlanta, GA

Sherine Thomas, MD is a community physician with board certifications in hematology, oncology and internal medicine. He has been practicing in Georgia for the last 13 years. During this time, he has been involved in management of complex cases in medical oncology both solid tumors, malignant hematology as well as benign hematology. This robust practice has allowed him to have an expansive understanding of the field and deliver more comprehensive care to his patients.

Dr. Thomas has also been a medical lab director for Northside Hospital cancer Institute oncology clinics in Conyers and Decatur, Georgia. In this role he has been involved in monitoring laboratory functions including credentialing, calibration, quality control of the hematology and oncology laboratory.

Dr. Thomas has a great interest in staying up to date with new and evolving therapies to make sure that the best available care is available for his patients who are frequently travel to Atlanta to receive such care. To this end he has frequently worked with faculty and physicians at Emory University and other tertiary academic oncology/hematology institutions.


Program Planning Committee


Charise Gleason, MSN, NP-BC, AOCNP (Content Co-Chair)

VP and Chief APP Officer, Adjunct Faculty

Nell Hodgson Woodruff School of Nursing

Emory Healthcare

Atlanta, GA

Charise Gleason, MSN, NP-BC, AOCNP®, is the VP and Chief Advanced Practice Officer for Emory Healthcare and adjunct faculty at the Nell Hodgson Woodruff School of Nursing at Emory University. She has been a nurse practitioner in the Multiple Myeloma program at the Winship Cancer Institute of Emory University for over twenty years. She earned both her bachelor’s and master’s degrees from Emory University and holds an advanced oncology certification through the ONCC. Ms. Gleason has been an active presenter and educator on the topics of multiple myeloma and has authored or co-authored many publications, including book chapters, abstracts, articles for nursing journals, and scientific publications.


Jesus G. Berdeja, M.D. (Content Co-Chair)

Director of Multiple Myeloma Research

The Greco-Hainsworth Tennessee Oncology Centers for Research

Nashville, TN

Jesus G. Berdeja received his undergraduate degree from Stanford University and medical degree from Harvard University. He completed his internship and residency in the Department of Internal Medicine at the University of California in San Francisco and fellowships in medical oncology and hematology at Johns Hopkins University School of Medicine in Baltimore.

Dr. Berdeja specializes in clinical hematology, with a focus on multiple myeloma. Additionally, he is an active member of several professional organizations, including the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, the International Myeloma Working Group and the Clinical Trials Myeloma Intergroup Committee. An active researcher, Dr. Berdeja has been the principal investigator many funded clinical trials in the field of multiple myeloma. He has published extensively in the peer-reviewed literature and is a frequent invited lecturer.


Disclosures:


Those others involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Other Contributors

All other non-faculty contributors and others involved in the planning, development and editing/review of the content disclosed no relevant financial relationships with any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients.

 

Charise Gleason, MSN, NP-C, AOCNP discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Jesús G. Berdeja, M.D. discloses contracted research with 2 Seventy Bio, Abbvie, Amgen, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Celularity, CRISPR Therapeutics, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno Therapeutics, K36 Therapeutics. Karyopharm, Lilly, Novartis, Poseida, Roche, Sanofi, Takeda, Consulting Fee's with AstraZeneca, BMS, Caribou Biosciences, Galapagos, Janssen, K36 Therapeutics, Kite Pharma, Legend Biotech, Pfizer, Regeneron, Roche, Sanofi, Sebia, Takeda and Speaker's Honoraria with Janssen during the past 24 months. 

Ajay Nooka, MD discloses that he is a consultant for AstraZeneca, Cellectar, GSK, Kite, Janssen, Pfizer, Sebia and Sanofi during the past 24 months.

Danielle Roberts, PA-C discloses that she is on an advisory board for Jadpro during the past 24 months.

Sarah A. Scott, PharmD discloses that she is on advisory boards for Johnson & Johnson, GSK, Pfizer and Sanofi as well as a consultant for Pfizer during the past 24 months. 

Available Credit

  • 2.00 AMA PRA Category 1 Credit

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 2.00 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 2.00 credit.
  • 0.75 Pharmacology
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 0.75 credit.

Price

Cost:
$0.00
Please login or register to take this course.

ATTENTION:  This limited-seating event is open exclusively for clinicians actively practicing in oncology as well as those cancer center employees directly involved in the design and development of outpatient clinics where bispecifics are administered to patients.  No pharmaceutical representatives will be seated for this event and their registrations will be declined.  We thank you for your understanding.